REVISTA-MSP FEBRERO 2025

A PCV for the prevention of IPD and pneumococcal pneumonia in adults

BRILLIANTLY DESIGNED FOR YOUR ADULT PATIENTS. 1-3 , a Only CAPVAXIVE is specifically designed for adults and covers the serotypes responsible on a national level for ~84% of adult IPD in the US—exceeding PCV20, which includes the serotypes that cause ~52%. 2,3,10,11 THE CDC RECOMMENDS CAPVAXIVE FOR 4,12,13 : Adults 50+: • Vaccine-naïve or vaccination history is unknown (lowered from 65+) Adults 19-49: • With certain chronic medical conditions or other risk factors † who are vaccine-naïve or vaccination history is unknown Previously Vaccinated Adults For Adults 19+: • Previously vaccinated with PCV13 only or PPSV23 only, ≥1 year prior at any age • Previously vaccinated but have not completed a recommended series b For Adults 65+: • As a supplemental dose for those previously vaccinated with PCV13 and PPSV23* * Routine if PCV13 was administered at any age and PPSV23 was administered before age 65 with the last pneumococcal vaccine being at least 5 years prior. Shared clinical decision-making if PCV13 was administered at any age and PPSV23 was administered at or after the age of 65 and the last pneumococcal vaccine was at least 5 years prior. 4 † Diabetes, renal disorders, chronic heart disease, chronic liver disease, chronic lung disease including asthma, smoking, alcoholism. 12

THAT’S BRILLIANT DESIGN A PCV specifically designed for adults and covers the serotypes responsible for most IPD cases 1-3,a

Encourage your appropriate adult patients to stay proactive with CAPVAXIVE. 14

VS by PCV20 1-3,a These values are based on CDC epidemiologic data and do not reflect the efficacy of the respective vaccines. 3 There are currently no studies comparing the efficacy of CAPVAXIVE and PCV20. a Based on CDC ABC surveillance data from the years 2018–2022, representing ~35 million persons and 10 states across the US. Regional variations may exist. 2-9 ~84% of US IPD cases in adults aged 50+ ~52% CAPVAXIVE was specifically designed for adults and helps protect against the serotypes that are responsible on a national level for a

Scan the QR code or go to capvaxivehcp.com to uncover more about the brilliant design behind CAPVAXIVE.

Actor Portrayal

a Based on CDC ABC surveillance data from the years 2018–2022, representing ~35 million persons and 10 states across the US. Regional variations may exist. 2-9 b Patients are eligible to receive CAPVAXIVE if they only received PCV13 or PPSV23 ≥1 year ago or if last dose of PPSV23 was completed ≥5 years ago where PCV13 and PPSV23 were both received. 4,12 Select Safety Information (continued) The most commonly reported (>10%) solicited adverse reactions in individuals 18 through 49 years of age who received CAPVAXIVE were: injection-site pain (73.1%), fatigue (36.0%), headache (27.5%), myalgia (16.4%), injection-site erythema (13.8%), and injection-site swelling (13.3%). The most commonly reported (>10%) solicited adverse reactions in individuals 50 years of age and older who received CAPVAXIVE were: injection-site pain (41.2%), fatigue (19.7%), and headache (11.0%). Vaccination with CAPVAXIVE may not protect all vaccine recipients. Please read the adjacent Brief Summary of the Prescribing Information. ABC, Active Bacterial Core; CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PCV20, 20-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; US, United States. References: 1. ABCs bact facts interactive data dashboard. SPN serotypes 1998-2022. Centers for Disease Control and Prevention. May 22, 2024. Accessed October 31, 2024. https://www.cdc.gov/ abcs/bact-facts/data-dashboard.html 2. Data available on request from Merck& Co., Inc., WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package US-PVV-00504. 3. 1998- 2022 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance, ages 18-49, 50-64, 65 plus, year is between 2018 and 2022. Centers for Disease Control and Prevention. Last updated July 22, 2024. Accessed October 31, 2024. https://data.cdc.gov/Public-Health-Surveillance/1998-2022-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p/ data 4. Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices – United States, 2024. MMWR Morb Mortal Wkly Rep . 2024;73(36):793-798. doi:10.15585/mmwr.mm7336a3 5. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae , 2018. Centers for Disease Control and Prevention. Updated May 22, 2020. Accessed October 31, 2024. https://stacks.cdc.gov/view/cdc/140450 6. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae , 2019. Centers for Disease Control and Prevention. Updated June 16, 2021. Accessed October 31, 2024. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf 7. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae , 2020. Centers for Disease Control and Prevention. Updated September 20, 2022. Accessed October 31, 2024. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2020.pdf 8. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae , 2021. Centers for Disease Control and Prevention. Updated June 2, 2023. Accessed October 31, 2024. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf 9. Active Bacterial Core surveillance (ABCs) report, Emerging Infections Program network, Streptococcus pneumoniae , 2022. Centers for Disease Control and Prevention. Updated July 5, 2024. Accessed November 1, 2024. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2022.pdf 10. Prevnar 20. Prescribing Information. Pfizer Inc; 2023. 11. Prevnar 13. Prescribing Information. Pfizer Inc; 2023. 12. Kobayashi M. Summary of work group interpretation of EtR and policy options: PCV use in adults aged ≥50 years. Slide deck presented at: Advisory Committee on Immunization Practices Meeting; October 23, 2024; Atlanta, GA. Accessed October 31, 2024. https://www.cdc.gov/acip/downloads/slides-2024- 10-23-24/04-Kobayashi-Pneumococcal-508.pdf 13. ACIP recommendations. Centers for Disease Control and Prevention. Last reviewed June 28, 2024. Accessed October 31, 2024. https://www.cdc. gov/vaccines/acip/recommendations.html 14. Immunizations for respiratory viruses prevention. Centers for Disease Control and Prevention. Last reviewed March 1, 2024. Accessed October 31, 2024. https://www.cdc.gov/respiratory-viruses/prevention/immunizations.html

Actor Portrayal

Indications and Usage CAPVAXIVE™ is indicated for:

Revista Puertorriqueña de Medicina y Salud Pública The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Select Safety Information Do not administer CAPVAXIVE to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid. Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE. (Select Safety Information continues on the next page) • active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older. • active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.

Made with FlippingBook Annual report maker